Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...

Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...

Pfizer announced Jeffrey Legos, PhD, MBA as its new chief oncology officer. Bluejay Therapeutics announced Mary Cromwell, PhD, has joined its leadership team as SVP and head of technical operations.

U.K.-based ad agency DAIVID said Pfizer had a strong, positive message with its ad and scored high with intense positive emotions. The commercial was also a top performer with spikes in positive ...

Leaked data showed that Pfizer’s mevrometostat has strong therapeutic potential in metastatic castration-resistant prostate ...

Alloy Therapeutics Inc., a biotechnology ecosystem company, has joined forces with Pfizer Inc., to develop a new platform ...

Pfizer's Super Bowl ad received mixed reactions on social media, but many criticized the pharma giant for saying it will ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

All this negativity, however, does open up an opportunity for investors to buy the stock at a discount. Despite being a top ...

Pfizer’s contributions to animal health date back several decades, during which the company played a significant role in ...

As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives ...

Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.